Latest Channelopathy Stories
- AIMing to establish a new treatment for ophthalmologic diseases - TOKYO, Oct. 14, 2014 /PRNewswire/ -- Astellas Pharma Inc.
SAN DIEGO, Oct.
ChanTest’s expertise will be showcased at the North American Cystic Fibrosis Conference this month, highlighting the important research the company has conducted to help move cystic fibrosis
CAMBRIDGE, England, October 6, 2014 /PRNewswire/ -- Agreement follows a very successful preceding collaboration with Dr Waxman with
NEW YORK, Oct.
LAUSANNE, Switzerland, October 1, 2014 /PRNewswire/ -- Sophia Genetics, the European leader in Clinical Genomics and Next Generation Sequencing (NGS) data analysis, today
Claire Wineland receives notable award for her dedication to making a difference in the lives of others living with cystic fibrosis Los Angeles, CA (PRWEB) September
Expanded Collaboration Supports Phase 2 Clinical Trial Initiation of First-In-Class ENaC Inhibitor for the Treatment of Cystic Fibrosis DURHAM, N.C., Sept.
- Recipients will compete for public votes for a chance to win one of two Thriving Undergraduate and Graduate Scholar awards NORTH CHICAGO, Ill., Aug.
Cystic fibrosis continues to be devastating for many people around the world.
Cystic fibrosis, also called mucoviscidosis, is an autosomal recessive genetic disorder of the viscous secretions in the body. In turn, it effects the lungs, pancreas, liver, and intestines, as well as all other exocrine glands in the body. The most common genetic mutation that causes CF is a deletion of three nucleotides that results in a loss of phenylalanine, an amino acid at the 508th position on the protein. It should be noted, however, that there are over a thousand other mutations that...
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.